TISIDB

Summary
Symbol	NLRP3
Name	NLR family, pyrin domain containing 3
Aliases	AGTAVPRL; AII; FCAS; FCU; NALP3; PYPAF1; MWS; CLR1.1; Cryopyrin; nucleotide-binding oligomerization domain, ......
Chromosomal Location	1q44
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm, cytosol Inflammasome Endoplasmic reticulum Secreted Nucleus Note=In macrophages, under resting conditions, mainly located in the cytosol, on the endoplasmic reticulum. After stimulation with inducers of the NLRP3 inflammasome, mitochondria redistribute in the vicinity of the endoplasmic reticulum in the perinuclear region, which results in colocalization of NLRP3 on the endoplasmic reticulum and PYCARD on mitochondria, allowing the activation of inflammasome assembly. After the induction of pyroptosis, inflammasome specks are released into the extracellular space where they can further promote IL1B processing and where they can be engulfed by macrophages. Phagocytosis induces lysosomal damage and inflammasome activation in the recipient cells (PubMed:24952504). In the Th2 subset of CD4(+) helper T-cells, mainly located in the nucleus. Nuclear localization depends upon KPNA2. In the Th1 subset of CD4(+) helper T-cells, mainly cytoplasmic (By similarity).
Domain	PF14484 Fish-specific NACHT associated domain PF13516 Leucine Rich repeat PF02758 PAAD/DAPIN/Pyrin domain
Function	As the sensor component of the NLRP3 inflammasome, plays a crucial role in innate immunity and inflammation. In response to pathogens and other damage-associated signals, initiates the formation of the inflammasome polymeric complex, made of NLRP3, PYCARD and CASP1 (and possibly CASP4 and CASP5). Recruitment of proCASP1 to the inflammasome promotes its activation and CASP1-catalyzed IL1B and IL18 maturation and secretion in the extracellular milieu. Activation of NLRP3 inflammasome is also required for HMGB1 secretion (PubMed:22801494). The active cytokines and HMGB1 stimulate inflammatory responses. Inflammasomes can also induce pyroptosis, an inflammatory form of programmed cell death. Under resting conditions, NLRP3 is autoinhibited. NLRP3 activation stimuli include extracellular ATP, reactive oxygen species, K(+) efflux, crystals of monosodium urate or cholesterol, amyloid-beta fibers, environmental or industrial particles and nanoparticles, cytosolic dsRNA, etc. However, it is unclear what constitutes the direct NLRP3 activator. Activation in presence of cytosolic dsRNA is mediated by DHX33 (PubMed:23871209). Independently of inflammasome activation, regulates the differentiation of T helper 2 (Th2) cells and has a role in Th2 cell-dependent asthma and tumor growth (By similarity). During Th2 differentiation, required for optimal IRF4 binding to IL4 promoter and for IRF4-dependent IL4 transcription. Binds to the consensus DNA sequence 5'-GRRGGNRGAG-3'. May also participate in the transcription of IL5, IL13, GATA3, CCR3, CCR4 and MAF (By similarity).

> Gene Ontology [ TOP ]
Biological Process	GO:0001818 negative regulation of cytokine production GO:0001819 positive regulation of cytokine production GO:0002237 response to molecule of bacterial origin GO:0002250 adaptive immune response GO:0002263 cell activation involved in immune response GO:0002285 lymphocyte activation involved in immune response GO:0002286 T cell activation involved in immune response GO:0002287 alpha-beta T cell activation involved in immune response GO:0002292 T cell differentiation involved in immune response GO:0002293 alpha-beta T cell differentiation involved in immune response GO:0002294 CD4-positive, alpha-beta T cell differentiation involved in immune response GO:0002366 leukocyte activation involved in immune response GO:0002367 cytokine production involved in immune response GO:0002369 T cell cytokine production GO:0002440 production of molecular mediator of immune response GO:0002443 leukocyte mediated immunity GO:0002449 lymphocyte mediated immunity GO:0002456 T cell mediated immunity GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002521 leukocyte differentiation GO:0002526 acute inflammatory response GO:0002673 regulation of acute inflammatory response GO:0002674 negative regulation of acute inflammatory response GO:0002694 regulation of leukocyte activation GO:0002696 positive regulation of leukocyte activation GO:0002697 regulation of immune effector process GO:0002699 positive regulation of immune effector process GO:0002700 regulation of production of molecular mediator of immune response GO:0002702 positive regulation of production of molecular mediator of immune response GO:0002703 regulation of leukocyte mediated immunity GO:0002705 positive regulation of leukocyte mediated immunity GO:0002706 regulation of lymphocyte mediated immunity GO:0002708 positive regulation of lymphocyte mediated immunity GO:0002709 regulation of T cell mediated immunity GO:0002711 positive regulation of T cell mediated immunity GO:0002718 regulation of cytokine production involved in immune response GO:0002720 positive regulation of cytokine production involved in immune response GO:0002724 regulation of T cell cytokine production GO:0002726 positive regulation of T cell cytokine production GO:0002819 regulation of adaptive immune response GO:0002821 positive regulation of adaptive immune response GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002824 positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0002828 regulation of type 2 immune response GO:0002830 positive regulation of type 2 immune response GO:0006606 protein import into nucleus GO:0006913 nucleocytoplasmic transport GO:0006919 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0007159 leukocyte cell-cell adhesion GO:0007249 I-kappaB kinase/NF-kappaB signaling GO:0009306 protein secretion GO:0009595 detection of biotic stimulus GO:0009615 response to virus GO:0010950 positive regulation of endopeptidase activity GO:0010952 positive regulation of peptidase activity GO:0017038 protein import GO:0022407 regulation of cell-cell adhesion GO:0022409 positive regulation of cell-cell adhesion GO:0030098 lymphocyte differentiation GO:0030217 T cell differentiation GO:0031348 negative regulation of defense response GO:0031503 protein complex localization GO:0032088 negative regulation of NF-kappaB transcription factor activity GO:0032102 negative regulation of response to external stimulus GO:0032386 regulation of intracellular transport GO:0032387 negative regulation of intracellular transport GO:0032496 response to lipopolysaccharide GO:0032611 interleukin-1 beta production GO:0032612 interleukin-1 production GO:0032616 interleukin-13 production GO:0032621 interleukin-18 production GO:0032633 interleukin-4 production GO:0032634 interleukin-5 production GO:0032651 regulation of interleukin-1 beta production GO:0032652 regulation of interleukin-1 production GO:0032656 regulation of interleukin-13 production GO:0032673 regulation of interleukin-4 production GO:0032674 regulation of interleukin-5 production GO:0032691 negative regulation of interleukin-1 beta production GO:0032692 negative regulation of interleukin-1 production GO:0032731 positive regulation of interleukin-1 beta production GO:0032732 positive regulation of interleukin-1 production GO:0032736 positive regulation of interleukin-13 production GO:0032753 positive regulation of interleukin-4 production GO:0032754 positive regulation of interleukin-5 production GO:0033157 regulation of intracellular protein transport GO:0034504 protein localization to nucleus GO:0035710 CD4-positive, alpha-beta T cell activation GO:0035743 CD4-positive, alpha-beta T cell cytokine production GO:0035745 T-helper 2 cell cytokine production GO:0042092 type 2 immune response GO:0042093 T-helper cell differentiation GO:0042110 T cell activation GO:0042306 regulation of protein import into nucleus GO:0042308 negative regulation of protein import into nucleus GO:0042345 regulation of NF-kappaB import into nucleus GO:0042347 negative regulation of NF-kappaB import into nucleus GO:0042348 NF-kappaB import into nucleus GO:0042990 regulation of transcription factor import into nucleus GO:0042991 transcription factor import into nucleus GO:0042992 negative regulation of transcription factor import into nucleus GO:0043122 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043124 negative regulation of I-kappaB kinase/NF-kappaB signaling GO:0043280 positive regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043281 regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043367 CD4-positive, alpha-beta T cell differentiation GO:0043370 regulation of CD4-positive, alpha-beta T cell differentiation GO:0043372 positive regulation of CD4-positive, alpha-beta T cell differentiation GO:0043433 negative regulation of sequence-specific DNA binding transcription factor activity GO:0044546 NLRP3 inflammasome complex assembly GO:0044744 protein targeting to nucleus GO:0045064 T-helper 2 cell differentiation GO:0045580 regulation of T cell differentiation GO:0045582 positive regulation of T cell differentiation GO:0045619 regulation of lymphocyte differentiation GO:0045621 positive regulation of lymphocyte differentiation GO:0045622 regulation of T-helper cell differentiation GO:0045624 positive regulation of T-helper cell differentiation GO:0045628 regulation of T-helper 2 cell differentiation GO:0045630 positive regulation of T-helper 2 cell differentiation GO:0045785 positive regulation of cell adhesion GO:0045862 positive regulation of proteolysis GO:0046631 alpha-beta T cell activation GO:0046632 alpha-beta T cell differentiation GO:0046634 regulation of alpha-beta T cell activation GO:0046635 positive regulation of alpha-beta T cell activation GO:0046637 regulation of alpha-beta T cell differentiation GO:0046638 positive regulation of alpha-beta T cell differentiation GO:0046822 regulation of nucleocytoplasmic transport GO:0046823 negative regulation of nucleocytoplasmic transport GO:0050663 cytokine secretion GO:0050701 interleukin-1 secretion GO:0050702 interleukin-1 beta secretion GO:0050704 regulation of interleukin-1 secretion GO:0050706 regulation of interleukin-1 beta secretion GO:0050707 regulation of cytokine secretion GO:0050708 regulation of protein secretion GO:0050709 negative regulation of protein secretion GO:0050710 negative regulation of cytokine secretion GO:0050711 negative regulation of interleukin-1 secretion GO:0050713 negative regulation of interleukin-1 beta secretion GO:0050714 positive regulation of protein secretion GO:0050715 positive regulation of cytokine secretion GO:0050716 positive regulation of interleukin-1 secretion GO:0050718 positive regulation of interleukin-1 beta secretion GO:0050727 regulation of inflammatory response GO:0050728 negative regulation of inflammatory response GO:0050863 regulation of T cell activation GO:0050865 regulation of cell activation GO:0050867 positive regulation of cell activation GO:0050870 positive regulation of T cell activation GO:0051047 positive regulation of secretion GO:0051048 negative regulation of secretion GO:0051051 negative regulation of transport GO:0051090 regulation of sequence-specific DNA binding transcription factor activity GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity GO:0051092 positive regulation of NF-kappaB transcription factor activity GO:0051169 nuclear transport GO:0051170 nuclear import GO:0051222 positive regulation of protein transport GO:0051224 negative regulation of protein transport GO:0051249 regulation of lymphocyte activation GO:0051251 positive regulation of lymphocyte activation GO:0051259 protein oligomerization GO:0051607 defense response to virus GO:0052547 regulation of peptidase activity GO:0052548 regulation of endopeptidase activity GO:0070486 leukocyte aggregation GO:0070489 T cell aggregation GO:0071216 cellular response to biotic stimulus GO:0071219 cellular response to molecule of bacterial origin GO:0071222 cellular response to lipopolysaccharide GO:0071396 cellular response to lipid GO:0071593 lymphocyte aggregation GO:0072538 T-helper 17 type immune response GO:0072539 T-helper 17 cell differentiation GO:0090317 negative regulation of intracellular protein transport GO:0098542 defense response to other organism GO:1900180 regulation of protein localization to nucleus GO:1900181 negative regulation of protein localization to nucleus GO:1902105 regulation of leukocyte differentiation GO:1902107 positive regulation of leukocyte differentiation GO:1902532 negative regulation of intracellular signal transduction GO:1902593 single-organism nuclear import GO:1903037 regulation of leukocyte cell-cell adhesion GO:1903039 positive regulation of leukocyte cell-cell adhesion GO:1903531 negative regulation of secretion by cell GO:1903532 positive regulation of secretion by cell GO:1903533 regulation of protein targeting GO:1903706 regulation of hemopoiesis GO:1903708 positive regulation of hemopoiesis GO:1903828 negative regulation of cellular protein localization GO:1904589 regulation of protein import GO:1904590 negative regulation of protein import GO:1904950 negative regulation of establishment of protein localization GO:1904951 positive regulation of establishment of protein localization GO:2000116 regulation of cysteine-type endopeptidase activity GO:2000316 regulation of T-helper 17 type immune response GO:2000318 positive regulation of T-helper 17 type immune response GO:2000319 regulation of T-helper 17 cell differentiation GO:2000321 positive regulation of T-helper 17 cell differentiation GO:2000514 regulation of CD4-positive, alpha-beta T cell activation GO:2000516 positive regulation of CD4-positive, alpha-beta T cell activation GO:2000551 regulation of T-helper 2 cell cytokine production GO:2000553 positive regulation of T-helper 2 cell cytokine production GO:2001056 positive regulation of cysteine-type endopeptidase activity
Molecular Function	GO:0005539 glycosaminoglycan binding GO:0008134 transcription factor binding GO:0042834 peptidoglycan binding
Cellular Component	GO:0044445 cytosolic part GO:0061702 inflammasome complex GO:0072559 NLRP3 inflammasome complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04621 NOD-like receptor signaling pathway
Reactome	R-HSA-5688426: Deubiquitination R-HSA-168256: Immune System R-HSA-622312: Inflammasomes R-HSA-168249: Innate Immune System R-HSA-392499: Metabolism of proteins R-HSA-5689901: Metalloprotease DUBs R-HSA-168643: Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways R-HSA-597592: Post-translational protein modification R-HSA-844456: The NLRP3 inflammasome

Summary
Symbol	NLRP3
Name	NLR family, pyrin domain containing 3
Aliases	AGTAVPRL; AII; FCAS; FCU; NALP3; PYPAF1; MWS; CLR1.1; Cryopyrin; nucleotide-binding oligomerization domain, ......
Chromosomal Location	1q44
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between NLRP3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between NLRP3 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
26384545	Colorectal Carcinoma	Promote immunity (NK cell function)	Here, we show that mice deficient in Nlrp3 inflammasome components had exacerbated liver colorectal cancer metastatic growth, which was mediated by impaired interleukin-18 (IL-18) signaling. Control of tumor growth was independent of differential cancer cell colonization or proliferation, intestinal microbiota effects, or tumoricidal activity by the adaptive immune system.
28442553	Pancreatic Carcinoma	Inhibit immunity (T cell function); essential for immunotherapy	NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma. Pharmacological inhibition or deletion of NLRP3, ASC (apoptosis-associated speck-like protein containing a CARD complex), or caspase-1 protected against PDA and was associated with immunogenic reprogramming of innate and adaptive immunity within the TME.
21159638	Melanoma	Inhibit immunity (T cell function)	We concluded that Nlrp3 was critical for accumulation of MDSCs in tumors and for inhibition of antitumor T-cell immunity after dendritic cell vaccination. Our findings establish an unexpected role for Nlrp3 in impeding antitumor immune responses, suggesting novel approaches to improve the response to antitumor vaccines by limiting Nlrp3 signaling.

Summary
Symbol	NLRP3
Name	NLR family, pyrin domain containing 3
Aliases	AGTAVPRL; AII; FCAS; FCU; NALP3; PYPAF1; MWS; CLR1.1; Cryopyrin; nucleotide-binding oligomerization domain, ......
Chromosomal Location	1q44
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of NLRP3 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	NLRP3
Name	NLR family, pyrin domain containing 3
Aliases	AGTAVPRL; AII; FCAS; FCU; NALP3; PYPAF1; MWS; CLR1.1; Cryopyrin; nucleotide-binding oligomerization domain, ......
Chromosomal Location	1q44
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of NLRP3 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.517	0.0971
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.666	0.264
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.409	0.411
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.925	0.102
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-1.583	0.369
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.095	0.966
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.215	0.61
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.385	0.672
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.088	0.925
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.314	0.0751
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.985	0.0523
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.444	0.0137

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of NLRP3 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	14.3	0	14.3	0.196
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	20	0	20	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	5.5	1.9	0.66
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	6.8	0.6	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	19	5.9	13.1	0.355
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	23.1	9.1	14	0.596
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	13.2	3.7	9.5	0.388
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	13.6	0	13.6	0.279
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	12.5	7.1	5.4	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	NLRP3
Name	NLR family, pyrin domain containing 3
Aliases	AGTAVPRL; AII; FCAS; FCU; NALP3; PYPAF1; MWS; CLR1.1; Cryopyrin; nucleotide-binding oligomerization domain, ......
Chromosomal Location	1q44
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NLRP3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	NLRP3
Name	NLR family, pyrin domain containing 3
Aliases	AGTAVPRL; AII; FCAS; FCU; NALP3; PYPAF1; MWS; CLR1.1; Cryopyrin; nucleotide-binding oligomerization domain, ......
Chromosomal Location	1q44
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NLRP3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NLRP3. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	NLRP3
Name	NLR family, pyrin domain containing 3
Aliases	AGTAVPRL; AII; FCAS; FCU; NALP3; PYPAF1; MWS; CLR1.1; Cryopyrin; nucleotide-binding oligomerization domain, ......
Chromosomal Location	1q44
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NLRP3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	NLRP3
Name	NLR family, pyrin domain containing 3
Aliases	AGTAVPRL; AII; FCAS; FCU; NALP3; PYPAF1; MWS; CLR1.1; Cryopyrin; nucleotide-binding oligomerization domain, ......
Chromosomal Location	1q44
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of NLRP3 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	NLRP3
Name	NLR family, pyrin domain containing 3
Aliases	AGTAVPRL; AII; FCAS; FCU; NALP3; PYPAF1; MWS; CLR1.1; Cryopyrin; nucleotide-binding oligomerization domain, ......
Chromosomal Location	1q44
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between NLRP3 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	NLRP3
Name	NLR family, pyrin domain containing 3
Aliases	AGTAVPRL; AII; FCAS; FCU; NALP3; PYPAF1; MWS; CLR1.1; Cryopyrin; nucleotide-binding oligomerization domain, ......
Chromosomal Location	1q44
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting NLRP3 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse NLRP3